Propiltiourasil ile indüklenen p-ANCA+ pyoderma gangrenozum: Olgu sunumu ve literatürün gözden geçirilmesi

Yıl 2020, Cilt: 12 Sayı: 2, 59 - 62, 30.08.2020

Sadettin Uslu , Aydan Köken Avşar , Ali Karakas

https://doi.org/10.35514/mtd.2020.30

Öz

Propiltiourasil (PTU), hipertiroidizm tedavisinde yaygın olarak kullanılan bir ilaçtır ve Graves hastalığı için tedavi edilen hastaların %20'sinde antinötrofil sitoplazmik antikorların (ANCA) gelişimi ile ilişkilidir [1], [2]. ANCA-pozitif PTU ile indüklenen pyoderma gangrenozum (PG) ilk olarak 1999'da Darben ve ark. [1]. ANCA'lar nekrotizan sistemik vaskülitli birçok hastanın kanında ve ilaca bağlı vaskülit, Sweet sendromu, Behçet hastalığı ve PG gibi nötrofilik dermatozlu bazı hastalarda bulunur. Bazı raporlar, PG'li hastalarda veya PG'nin özellikleri ile nötrofilik dermatozlu hastalarda ANCA fenomenini tanımlamıştır [3]. Bu olgu bazlı derleme ile uzun süredir PTU kullanan bir hastada p-ANCA pozitifliği olan PG gelişimini sunmayı ve güncel literatürü tartışmayı amaçladık.

Anahtar Kelimeler

ANCA, PTU, Pyoderma Gangrenosum

Propylthiouracil induced p-ANCA+ pyoderma gangrenosum: Case report and review of literature

Öz

Propylthiouracil (PTU) is a medication commonly used in the treatment of hyperthyroidism and is associated with the development of antineutrophil cytoplasmic antibodies (ANCA) in 20% of patients treated for Graves’ disease [1], [2]. ANCA-positive PTU-induced pyoderma gangrenosum (PG) was first identified in 1999 by Darben et al. [1]. ANCAs are found in the blood of many patients with necrotizing systemic vasculitis and in some patients with neutrophilic dermatoses such as drug-induced vasculitis, Sweet’s syndrome, Behçet's disease and PG. Some reports have described the ANCA phenomenon in patients with PG or in neutrophilic dermatosis with the characteristics of PG [3]. We aimed to present development of PG with p-ANCA positivity in a patient who had been using PTU for a long time and to discuss the current literature with this case-based review.

Anahtar Kelimeler

ANCA, PTU, Pyoderma Gangrenosum, Vasculitis

Kaynakça

• T. Darben, J. Savige, R. Prentice, B. Paspaliaris, and J. Chick, “Pyoderma gangrenosum with secondary pyarthrosis following propylthiouracil,” Australas. J. Dermatol., 1999.
• R. M. Miller, T. A. Darben, J. Nedwich, and J. Savige, “Propylthiouracil-induced antineutrophil cytoplasmic antibodies in a patient with Graves’ disease and a neutrophilic dermatosis [13],” British Journal of Dermatology. 1999.
• K. Gungor, S. Gonen, G. Kisakol, O. Dikbas, and A. Kaya, “ANCA positive propylthiouracil induced pyoderma gangrenosum [2],” Journal of Endocrinological Investigation. 2006.
• B. R., “Management of pyoderma gangrenosum - An update,” Indian J. Dermatol. Venereol. Leprol., 2004.
• J. Reichrath, G. Bens, A. Bonowitz, and W. Tilgen, “Treatment recommendations for pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patients,” Journal of the American Academy of Dermatology. 2005.
• P. Al Ghazal, A. Körber, J. Klode, and J. Dissemond, “Investigation of new co-factors in 49 patients with pyoderma gangrenosum,” JDDG J. der Dtsch. Dermatologischen Gesellschaft, 2012.
• S. B. Hong and M. H. Lee, “A Case of Propylthiouracil-Induced Pyoderma gangrenosum Associated with Antineutrophil Cytoplasmic Antibody,” Dermatology, 2004.
• B.-V. A. et al., “Neutrophilic dermatosis associated with propylthiouracil-induced p-ANCA (p-antineutrophil cytoplasmic antibodies),” Ann. Dermatol. Venereol., 2005.
• J. W. Seo, H. H. Son, J. H. Choi, and S. K. Lee, “A case of p-ANCA-positive propylthiouracil-induced pyoderma gangrenosum,” Ann. Dermatol., 2010.
• J. Y. Noh et al., “Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves’ disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations,” Clin. Endocrinol. (Oxf)., 2001.
• N. Sera et al., “Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves’ disease,” Thyroid, 2000.
• J. E. Gunton, J. Stiel, P. Clifton-Bligh, E. Wilmshurst, and A. McElduff, “Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication,” Eur. J. Endocrinol., 2000.
• M. C. Slot, T. P. Links, C. A. Stegeman, and J. W. C. Tervaert, “Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study,” Arthritis Care Res., 2005.
• S. S. Dhillon, D. Singh, N. Doe, A. M. Qadri, S. Ricciardi, and M. I. Schwarz, “Diffuse alveolar hemorrhage and pulmonary capillaritis due to propylthiouracil,” Chest, 1999.
• O. Panamonta, V. Sumethkul, P. Radinahmed, M. Laopaiboon, and W. Kirdpon, “Propylthiouracil associated antineutrophil cytoplasmic antibodies (ANCA) in patients with childhood onset graves’ disease,” J. Pediatr. Endocrinol. Metab., 2008.
• H. Sato et al., “High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset graves’ disease treated with propylthiouracil,” J. Clin. Endocrinol. Metab., 2000.
• Y. X. Chen et al., “Propylthiouracil-associated antineutrophil cytoplasmic autoantibody- positive vasculitis: Retrospective study of 19 cases,” J. Rheumatol., 2007.
• C. Geffriaud-Ricouard, L. H. Noël, D. Chauveau, S. Houhou, J. P. Grünfeld, and P. Lesavre, “Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients,” Clin. Nephrol., 1993.
• S. Kimura and M. Ikeda‐Saito, “Human myeloperoxidase and thyroid peroxidase, two enzymes with separate and distinct physiological functions, are evolutionarily related members of the same gene family,” Proteins Struct. Funct. Bioinforma., 1988.
• X. Jiang, G. Khursigara, and R. L. Rubin, “Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils,” Science (80-. )., 1994.
• S. Von Schmiedeberg, C. Goebel, E. Gleichmann, and J. Uetrecht, “Neutrophils and drug metabolism,” Science. 1995.
• J. Y. Wang, L. E. French, N. H. Shear, A. Amiri, and A. Alavi, “Drug-Induced Pyoderma Gangrenosum: A Review,” American Journal of Clinical Dermatology. 2018.
• R. M. Bhat, “Management of pyoderma gangrenosum--an update,” Indian J Dermatol Venereol Leprol, 2004.
• W. U., “Pyoderma gangrenosum-a systemic disease?,” Clin. Dermatol., 2015.
• D. T.S. and D. M.D.P., “Diagnosis and treatment of the neutrophilic dermatoses (pyoderma gangrenosum, Sweet’s syndrome),” Dermatol. Ther., 2011.